Enlogics Secures Nearly RMB 150 Million Series A Funding to Accelerate R&D and Industrialization of Synthetic Biology Products
Shanghai Yinuojike Biotechnology Co., Ltd. (hereinafter referred to as “Yinuojike”) announced that it has recently successfully completed its Series A financing round of nearly RMB 150 million, led byAriose Capital, Zhangjiang HaohengLead Investor,Hefei Industrial Investment, Flyfot VenturesCo-investment, Existing ShareholdersXincheng FundAdditional Investment.China's Leading Listed Industrial CompanyHengxing New Materials (603276.SH)ParticipationStrategic Investment. Since its establishment, the company has demonstrated strong performance in the capital markets, securing cumulative financing of nearly RMB 300 million. Continuous funding from top-tier investment institutions and industry partners underscores InoKiko’s exceptional development potential and market value in the field of synthetic biology, while providing robust momentum to accelerate the research, development, and industrialization of its green biomanufacturing products.
Yinuo Keke is an innovative enterprise engaged in the research, development, and industrialization of synthetic biology, with products spanning natural flavors, pharmaceuticals and general health, and bio-based chemicals. The company is committed to building an internationally leading integrated platform for green biotechnology. Having completed the construction of its R&D center, pilot-scale workshop, and scale-up production base, Yinuo Keke has established a robust foundation for product development and large-scale manufacturing, positioning it to better meet the urgent domestic and international demand for pure, natural, and green biomanufactured products.
InoKeko was co-founded by industry-leading experts, including Chu Xiaohe, former chief engineer of a major publicly listed industrial company, and Professor Ye Bangce from the School of Biotechnology at East China University of Science and Technology. The company has attracted and assembled senior technical and commercialization talents from top-tier domestic and international chemical and synthetic biology enterprises, with an average of over 20 years of industry experience and extensive expertise in R&D, scaled-up manufacturing, and market sales.
Since its inception, Inokoko has focused on natural flavors as its core product line, targeting a broad downstream market, and has gradually expanded its business into the fields of biopharmaceuticals and nutritional health, demonstrating a differentiated product selection strategy and a diversified development trajectory. The company’s outstanding performance has earned widespread industry recognition, including awards such as the Biomanufacturing Special Award at the 24th China International Industry Fair (CIIF), the Synbio China 2024 Excellence Brand in Synthetic Biology and Biomanufacturing, and the SIA100 Annual Technological Achievement Award, further underscoring its strength and market position.
Upon the completion of this financing round, the Company will continue to strengthen its technology platform construction and accelerate the implementation and application of new quality productive forces, such as large AI models, in core areas including enzyme mining and optimization, as well as fermentation process optimization and scale-up. This will further enhance R&D efficiency and expedite the industrialization of products. Meanwhile, leveraging the robust industrial and commercialization resources of both existing and new shareholders, the Company will continue to identify and deploy bio-manufacturing products with substantial market potential and clear advantages in cost and quality, thereby driving the upgrading and transformation of related downstream industries.
InnoCare stated:We extend our sincere gratitude to all new and existing shareholders for their strong recognition and steadfast support. Through this round of financing, InoGeek will bolster its financial strength and leverage enhanced shareholder resources. The company will further upgrade its technology platforms and production facilities, integrating cutting-edge domestic and international technologies to continuously improve R&D and manufacturing efficiency. 2025 is poised to be a year of rapid performance growth for InoGeek, as multiple products in high market demand have entered the commercialization stage. Moreover, the large-scale industrial production base has been officially put into operation, ensuring high-quality and safe production. In addition, the company has established commercialization channels for several core products, providing robust support for the sustainable growth of future orders and revenue. InoGeek will accelerate the R&D and industrialization of a series of competitive synthetic biology products, actively explore collaborations with leading domestic and international enterprises, and jointly promote the development and expansion of China’s synthetic biology and bio-manufacturing industries.
Ariose Capital stated:Inokiko is a representative enterprise of China’s new quality productive forces in biomanufacturing. We highly recognize the founding team’s low-profile and pragmatic work philosophy, and we are very optimistic about the trend of synthetic biology frontier technologies empowering the upgrading and transformation of traditional industries. We believe that Inokiko can effectively leverage its core advantages in technology and industrialization, continuously provide the market with biomanufacturing products featuring quality and cost advantages, and constantly empower top-tier industry partners to achieve greater end-user value.
Zhang Jiang Haoheng stated:In the highly promising field of synthetic biology, InoKeco has demonstrated unique competitive advantages. The company boasts a top-tier expert team and possesses robust end-to-end capabilities spanning from product research and development to commercialization. Its forward-looking layout across multiple sectors, including natural flavors and fragrances as well as pharmaceuticals and general health, positions it strategically for future growth. Currently, the market demand for green bio-manufacturing is expanding rapidly, and InoKeco’s technologies and products are well-aligned with this trend. With this investment, we are not only optimistic about its short-term commercial potential but also place greater emphasis on its long-term role in driving the entire synthetic biology industry. Moving forward, Zhangjiang Haoheng will fully leverage its resource advantages to support InoKeco in deepening its efforts in technological innovation and industrial expansion. Together, we aim to build a leading enterprise in the field of synthetic biology, spearhead innovative development trends within the industry, and contribute to the prosperity of the green bio-manufacturing sector.
Hengxing New Materials stated:As an industry partner deeply rooted in the field of green specialty chemicals, Hengxing New Materials highly recognizes Inojico’s forward-looking layout and technological breakthroughs in synthetic biology. This strategic investment is not merely a collaboration at the capital level, but also a deep practice of industrial chain synergy and technological complementarity between both parties. With natural flavors as its entry point, Inojico has built a green bio-manufacturing platform that aligns closely with Hengxing New Materials’ global supply chain advantages in fragrances, flavors, and synthetic biology. In the future, we will leverage our own industrialization experience and market-oriented resources to accelerate the large-scale implementation of Inojico’s core products, jointly expand the application boundaries of bio-based chemicals in high-value-added fields, and help China’s synthetic biology industry reach the international forefront. We look forward to both parties taking “joint R&D, shared capacity expansion, and collaborative market advancement” as pivots to provide more competitive green solutions for global customers!
Hefei Industrial Investment Holdings stated:As a pioneering innovative enterprise at the forefront of commercialization in synthetic biology, InoKeco demonstrates its competitive advantages and growth potential through its leading technology platform and diversified product portfolio. This investment not only signifies full recognition of the company’s development prospects but also represents a strategic move by Hefei Industrial Investment Group in the field of biomanufacturing. Moving forward, Hefei Industrial Investment Group will leverage regional advantages to foster synergy between InoKeco and the local industrial chain, driving sustained innovative development.
Flyfot Ventures stated:Synthetic biology has been one of our key focus areas in recent years. The InoKiko team possesses extensive experience in strain development and fermentation scale-up, having developed multiple chassis strains and metabolic pathways, while maintaining a clear strategic positioning in product selection. Several product pipelines have already achieved commercialization, and we continue to iteratively optimize strain metabolism and process routes to sustain our leading advantage in both cost and quality. We look forward to InoKiko’s growth into a leading synthetic biology platform company in China.
Ariose Capital focuses on equity investments in the healthcare and medical industry. Its core limited partners include more than ten publicly listed healthcare companies, state-owned enterprises, market-oriented fund-of-funds, and local governments. Distinguished by its “ecosystem investment strategy” and “comprehensive post-investment empowerment,” Ariose Capital leverages the advantageous resources of industry-listed companies and its team to build a comprehensive health industry ecosystem, while making deep investment layouts closely aligned with ecosystem resources. Meanwhile, it fully utilizes these ecosystem resources to provide a series of post-investment value-added services to portfolio companies, facilitating their robust development and delivering superior returns to the fund’s investors.
Shanghai Zhangjiang Haoheng Innovation Equity Investment Management Co., Ltd. is an equity investment management company established in late 2019, with Zhangjiang Hi-Tech (600895.SH) as the primary sponsor, in partnership with Pudong Venture Capital and Pudong Construction. The company focuses on technology-driven innovative enterprises in sectors such as integrated circuits, biopharmaceuticals and medical devices, next-generation information technology, and intelligent manufacturing. The assets under management of its current funds (Zhangjiang Suifeng Fund and Zhangjiang Suifeng Phase II Fund) exceed RMB 3 billion.
Jiangsu Hengxing New Material Technology Co., Ltd. is a high-tech enterprise in Jiangsu Province that successfully listed on the Main Board of the Shanghai Stock Exchange in September 2023. The company specializes in the development, production, and sales of organic ketones, acids, and esters. Its products are primarily applied in green sectors such as highly efficient, low-toxicity, and environmentally friendly pesticides, lithium-ion battery electrolytes, flavors and fragrances, and eco-friendly coatings. It has become a major global supplier of products including 3-pentanone, methyl isopropyl ketone, propionate esters, n-butyric acid, isobutyric acid, and n-valeric acid, with comprehensive strengths that are internationally competitive.
Hefei Industrial Investment is a state-owned capital operation company positioned for industrial investment and financing as well as innovation promotion. The group holds equity stakes in more than ten listed companies, including Guofeng New Materials, supports the implementation of key industrial projects such as ChangXin Memory Technologies (CXMT), and has established a full-lifecycle fund cluster to exert dual efforts in both developing industries and investing in industries.
Flyfot Ventures, established in 2015, is an investment firm founded by Tsinghua University alumni that focuses on the fields of hard technology and biomedicine. The team possesses extensive industry resources, with its primary investment directions being semiconductors, advanced manufacturing, new energy and new materials, and biomedicine. Its core philosophy is to grow alongside entrepreneurs. Typical investment cases of Flyfot Ventures include: Maxscend Microelectronics (300782), Chipower, XinGui Juhe, Feimian Instruments, Yuchi Vacuum, Lingguang Infrared, Knowm Technology, Shimode Micro, Lemon Photonics, Haidever, Fengyuan Hydrogen Energy, Yins Robotics, Future Robotics, Yifei Automation, Hadesen Zhicai, CAS Jiuyuan, Qina New Energy, Visum Imaging, and Boda Medical.
Xincheng Fund was established in 2021, initiated and led by Innovent Biologics Group, and operates independently. Currently, Xincheng Fund manages one venture capital fund—the Suzhou Xinhe Guoqing Fund. This venture capital fund was jointly initiated by Innovent Biologics and Yuanhe Holdings as general partners, with its operations led by Innovent Biologics. The fund aims to actively implement the national innovation-driven development strategy, focus on frontier opportunities in the life and health industry, leverage industrial strengths and distinctive advantages, and support the high-quality development of innovative enterprises. It specializes in investing in leading companies in innovative drugs, biotechnology, and related segments of the industry chain, with an emphasis on empowering next-generation biopharmaceuticals and breakthrough technologies to address unmet clinical needs.